Morgan Stanley cuts Exelixis target price to $57 from $60
EXEL•Morgan Stanley cut its target price for Exelixis to $57 from $60.
Related News
EMA's CHMP recommends indication extensions for Bexsero and Talzenna
GSK•
European stocks near record highs, dollar gains on rate hike bets
SPY•
Prudential files next-day disclosure with HKEX announcing share buyback and cancellation
PUK•
Kohl's target price raised to $18 from $15 by Morgan Stanley
KSS•
Acadia Pharmaceuticals Inc.: Morgan Stanley cuts target price to $24 from $28
ACAD•